Stock Update (NASDAQ:VRTX): Vertex Awards $1 Million in Grants to 18 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis

[ Business Wire] – Vertex Pharmaceuticals Incorporated today announced it has awarded the company’s 2016 Cystic Fibrosis Circle of Care grants, totaling approximately $1 million, to 18 non-profit medical, academic, patient and community organizations. Read more on this. Vertex Pharmaceuticals Incorporated (VRTX) , currently valued at $21.06B, began trading this morning at $84.12. Shares have traded today between $82.44 and $85.65 per share with a one year range of $78.51 to $143.45. VRTX shares are currently priced at 39.30x this year’s forecasted earnings, which makes them relatively expensive compared to the industry ’s -1.62x forward p/e ratio. In a review of the consensus earnings estimate this quarter, 19 sell-side analysts are looking at $0.32 per share, which would be $0.32 worse than the year-ago quarter and a $0.10 sequential decrease. Investors should also note that the full-year EPS estimate of $2.17 is a $3.28 better when compared to the previous year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $451.54 Million. If realized, that would be a 226.02% increase over the year-ago quarter. Recently, Jefferies upgraded VRTX from Hold to Buy (Feb 1, 2016). Previously, Credit Suisse Initiated VRTX at to Outperform. With the above information in mind, readers should note that the average price target is $132.29, which is 57.26% above where the stock opened this morning. See more in (NASDAQ:VRTX) Similar Articles: Stock Update: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – What Vertex’s Results Mean for Corbus, ProQR, and Nivalis Market Update: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Vertex Receives Complete Response Letter from U.S. FDA for Use of KALYDECO® (ivacaftor) in People with Cystic Fibrosis Ages 2 and Older with One of 23 Residual Function Mutations Company Update (NASDAQ:VRTX): Vertex Announces Significant Progress in Its Development Efforts to Treat the Cause of Cystic Fibrosis in the Vast Majority of People with the Disease
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.